Venus Remedies reported a consolidated net profit of ₹102.78 crore for the financial year ended March 31, 2026, marking a substantial increase from ₹45.31 crore in the prior year. Revenue from operations for the period stood at ₹769.60 crore, compared to ₹652.89 crore in FY25, while total income increased to ₹782.18 crore from ₹668.84 crore. The company's board has recommended a final dividend of ₹10 per equity share, subject to shareholder approval at the upcoming Annual General Meeting scheduled for August 20, 2026.

The standalone financial results for FY26 reflected a similar upward trajectory, with net profit reaching ₹99.31 crore, up from ₹52.55 crore in the previous year. Standalone revenue from operations grew to ₹768.73 crore from ₹644.47 crore. The statutory auditors, J.K. Jain & Associates, issued an unmodified opinion on both the standalone and consolidated financial results, confirming compliance with Indian Accounting Standards and SEBI Listing Regulations.

Annual Financial Performance

The following table outlines the consolidated financial performance for the year ended March 31, 2026, compared to the previous year:

Q4 Quarterly Performance

Venus Remedies delivered a strong quarterly performance, with consolidated net profit more than doubling to ₹47.49 crore in Q4 compared to ₹21.00 crore in the same period of the previous year. Revenue for the quarter rose to ₹259.40 crore from ₹197.66 crore year-on-year, reflecting robust top-line growth. EBITDA for the quarter expanded significantly to ₹68.37 crore from ₹35.77 crore, while EBITDA margin improved sharply to 25.86% from 18.10% in the year-ago period.

Corporate Governance and Appointments

The board approved the re-appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director for a period of five years effective from October 1, 2026, and Dr. (Mrs.) Savita Gupta as Non-Executive Independent Director for a second term of five years effective from December 29, 2026. Additionally, Mr. Saransh Chaudhary was appointed as an Additional Director (Whole Time Director) and Dr. Gurminder Singh Bedi as an Additional Director (Non-Executive Independent Director), both for five years starting May 26, 2026. All appointments are subject to shareholder approval.

The board also appointed M/s C. L. Bansal & Associates as Cost Auditors and M/s Mehra Goel & Co as Internal Auditors for FY 2026-27. Furthermore, the company proposed adopting new Memorandum and Articles of Association to align with the Companies Act, 2013, pending shareholder approval. The trading window for designated persons remains closed until 48 hours after the declaration of financial results.

Venus Remedies has secured approval from the Saudi Food and Drug Authority (Saudi FDA) for Plerixafor, a specialty cancer treatment. This regulatory clearance marks the company's first global marketing authorization for this product, representing a notable milestone in its oncology portfolio.

Regulatory Milestone in Oncology

The Saudi FDA approval for Plerixafor underscores Venus Remedies' expanding presence in the specialty pharmaceutical segment. Plerixafor is recognized as a specialty cancer treatment, and this authorization from the Saudi FDA constitutes the company's first global marketing approval for the drug.

Significance of the Approval

Obtaining a marketing authorization from the Saudi FDA is a key regulatory achievement for Venus Remedies, enabling the company to commercialize Plerixafor in the Saudi Arabian market. This first global marketing authorization for Plerixafor highlights the company's efforts to expand its specialty oncology offerings across international markets.